Market Overview

UPDATE: Piper Jaffray Initiates Galena Biopharma at Overweight on ImmunoRx Potential

Related GALE
Galena Biopharma Inducts Mary Ann Gray To Its Board
Galena Biopharma 2016 Outlook Focuses On 'High Value' Cancer Immunotherapy Pipeline

Piper Jaffray initiated coverage on Galena Biopharma (NASDAQ: GALE) with an Overweight rating and a $2.50 price target.

Piper Jaffray commented, "Galena is a cancer immunotherapy company that is developing NeuVax, which could be a new blockbuster breast cancer adjuvant therapy. Galena should complete enrollment of the Phase III PRESENT trial this summer with 36-month Disease Free Survival (DFS) data in mid-2016. Galena is also developing a Folate Binding Protein E39 (FBP-E39) targeted vaccine in a Phase I/II ovarian and endometrial cancer trial with preliminary data at ASCO in June. We look for clinical progress and potential partnerships to drive shareholder value in 2013. Galena recently raised $24 million, which should fund the company into 2014."

Galena Biopharma closed at $1.55 on Friday.

Latest Ratings for GALE

Mar 2016Roth CapitalMaintainsBuy
Dec 2015Cantor FitzgeraldUpgradesSellHold
Nov 2015OppenheimerUpgradesPerformOutperform

View More Analyst Ratings for GALE
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Initiation Pre-Market Outlook Analyst Ratings


Related Articles (GALE)

View Comments and Join the Discussion!